ZA200904676B - Modulators of sclerostin binding partners for treating bonerelated disorders - Google Patents

Modulators of sclerostin binding partners for treating bonerelated disorders

Info

Publication number
ZA200904676B
ZA200904676B ZA200904676A ZA200904676A ZA200904676B ZA 200904676 B ZA200904676 B ZA 200904676B ZA 200904676 A ZA200904676 A ZA 200904676A ZA 200904676 A ZA200904676 A ZA 200904676A ZA 200904676 B ZA200904676 B ZA 200904676B
Authority
ZA
South Africa
Prior art keywords
bonerelated
modulators
disorders
treating
binding partners
Prior art date
Application number
ZA200904676A
Other languages
English (en)
Inventor
Chris Xiangyang Lu
Shou-Lh Hu
Michaela Kneissel
Christine Halleux
Original Assignee
Novertis A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novertis A G filed Critical Novertis A G
Publication of ZA200904676B publication Critical patent/ZA200904676B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
ZA200904676A 2007-02-02 2009-07-03 Modulators of sclerostin binding partners for treating bonerelated disorders ZA200904676B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88795607P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
ZA200904676B true ZA200904676B (en) 2010-04-28

Family

ID=39298321

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904676A ZA200904676B (en) 2007-02-02 2009-07-03 Modulators of sclerostin binding partners for treating bonerelated disorders

Country Status (16)

Country Link
US (3) US20100028335A1 (es)
EP (1) EP2114435A1 (es)
JP (1) JP2010526766A (es)
KR (1) KR20090115133A (es)
CN (1) CN101616684A (es)
AU (1) AU2008209713B2 (es)
BR (1) BRPI0807205A2 (es)
CA (1) CA2675639A1 (es)
EA (1) EA200901031A1 (es)
IL (1) IL199834A0 (es)
MA (1) MA31156B1 (es)
MX (1) MX2009008096A (es)
NZ (1) NZ578235A (es)
TN (1) TN2009000323A1 (es)
WO (1) WO2008092894A1 (es)
ZA (1) ZA200904676B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101469329B (zh) 1998-11-27 2012-10-24 达尔文发现有限公司 增加骨矿化的组合物和方法
EA015166B1 (ru) 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US8541177B2 (en) * 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
CA2748500C (en) * 2009-01-29 2017-10-17 Commonwealth Scientific And Industrial Research Organisation Measuring g protein coupled receptor activation
BR112012028920B1 (pt) 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
US8614190B2 (en) 2010-06-30 2013-12-24 Industrial Technology Research Institute Thermal responsive composition for treating bone diseases
EP2412724A1 (en) * 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulation of Glypican 4 activity to modulate the fate of stem cells and uses thereof
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
SG193610A1 (en) 2011-03-25 2013-11-29 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
PL3404041T3 (pl) 2011-04-19 2020-12-14 Amgen Inc. Sposób leczenia osteoporozy
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
HUE039786T2 (hu) 2011-08-04 2019-02-28 Amgen Inc Csonthiány-defektusok kezelési módszere
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US9708375B2 (en) * 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
WO2015098112A1 (ja) * 2013-12-27 2015-07-02 独立行政法人医薬基盤研究所 食道がんのマーカーおよびその利用
MX2016008982A (es) * 2014-01-13 2016-09-09 Imp Innovations Ltd Materiales biológicos y usos terapéuticos de los mismos.
AU2015207665B2 (en) * 2014-01-17 2021-04-15 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease
CN107922951B (zh) * 2015-06-24 2022-01-14 学校法人庆应义塾 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3496744A1 (en) 2016-08-08 2019-06-19 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
TWI667253B (zh) * 2016-12-30 2019-08-01 博晟生醫股份有限公司 重組多肽、核酸分子及其組合物以及製造、使用之方法
MX2020010092A (es) 2018-03-30 2020-10-28 Amgen Inc Variantes de anticuerpo c-terminales.
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
WO2019246179A1 (en) * 2018-06-22 2019-12-26 The Trustees Of Columbia University In The City Of New York Sustained release compositions and methods for treatment of temporomandibular joint degeneration
CN112702991A (zh) 2018-08-10 2021-04-23 安进公司 制备抗体药物配制品的方法
CN109734795B (zh) * 2019-01-17 2022-07-12 武汉明德生物科技股份有限公司 人Lrp4抗原、人Lrp4抗体检测试剂盒及其制备方法与应用
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
US20220275073A1 (en) 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations
CN112656806B (zh) * 2020-12-24 2022-08-26 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 多配体蛋白聚糖4的siRNA序列在抑制犬瘟热病毒复制中的应用
CN113913463B (zh) * 2021-09-19 2023-08-18 郭保生 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用
WO2023114930A1 (en) * 2021-12-15 2023-06-22 The George Washington University Compositions for and methods of improving directed evolution of biomolecules
CN114984225B (zh) * 2022-06-22 2024-02-02 中山大学附属第八医院（深圳福田） hsa_circ_0005773在防治间充质干细胞衰老及骨关节炎中的应用
CN117169521A (zh) * 2023-08-25 2023-12-05 暨南大学附属第一医院（广州华侨医院） 一种种植体周围炎质谱负离子模式代谢组学生物标志物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008304C (en) * 1989-01-31 2001-03-27 Craig S. Hill Assay for bone alkaline phosphatase
JP2003526370A (ja) * 2000-03-16 2003-09-09 アムジェン インコーポレーテッド Ｉｌ−１７レセプター様分子およびその使用
EP1274726B1 (en) * 2000-04-13 2009-12-23 Thomas N. Wight Therapeutic compounds and methods for modulating v3, a versican isoform
AU2002258592A1 (en) * 2001-03-23 2002-11-25 The Burnham Institute Compositions and methods for modulating bone mineral deposition
EP2277522B1 (en) * 2002-03-01 2012-11-21 UCB Manufacturing, Inc. Methods for increasing or decreasing bone density and identifying molecules
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
EP1608399B1 (en) * 2003-03-14 2012-01-11 Ucb Manufacturing, Inc. Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex
JP2007521015A (ja) * 2003-09-18 2007-08-02 ジェンマブ エー／エス 癌の診断及び治療に用いられる示差的に発現する腫瘍特異的ポリペプチド
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2005070965A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases
CN101061217A (zh) * 2004-02-27 2007-10-24 通用医疗公司 用于毛发生长的方法和组合物
US20080199437A1 (en) * 2004-07-22 2008-08-21 Eisai Co., Ltd. Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
EP1950292A4 (en) * 2005-08-18 2009-01-21 Eisai R&D Man Co Ltd Nato3, DOPAMINE PRODUCER NEURONE GROWTH PROGENITOR CELL MARKER
US8541177B2 (en) * 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction

Also Published As

Publication number Publication date
JP2010526766A (ja) 2010-08-05
EA200901031A1 (ru) 2010-04-30
IL199834A0 (en) 2010-04-15
AU2008209713A1 (en) 2008-08-07
US20130164284A1 (en) 2013-06-27
NZ578235A (en) 2012-05-25
EP2114435A1 (en) 2009-11-11
CN101616684A (zh) 2009-12-30
US20120003219A1 (en) 2012-01-05
CA2675639A1 (en) 2008-08-07
US20100028335A1 (en) 2010-02-04
AU2008209713B2 (en) 2012-01-19
MX2009008096A (es) 2009-08-07
TN2009000323A1 (en) 2010-12-31
BRPI0807205A2 (pt) 2014-07-22
KR20090115133A (ko) 2009-11-04
MA31156B1 (fr) 2010-02-01
WO2008092894A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
ZA200904676B (en) Modulators of sclerostin binding partners for treating bonerelated disorders
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
HK1212883A1 (zh) 治療眼部疾病的方法
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
IL194739A0 (en) Dihydrothienopyrimidine for treating inflammatory disorders
GB0617734D0 (en) Method of treating peripheral nerve disorders
ZA200807715B (en) 9-Heteroarylpurine MNK2 inhibitors for treating metabolic disorders
EP2323667A4 (en) MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
AU2007288337A8 (en) Compounds for treating proliferative disorders
GB2467710B (en) Methods for treating social disorders
EP2142206A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
EP1993589A4 (en) TREATMENTS FOR NEUROLOGICAL DISORDERS
EP2174914A4 (en) PROCESS FOR TREATING DIARSENIC TRIOXIDE
PL2061501T3 (pl) Sposób leczenia zaburzeń oddechowych
IL198352A0 (en) Modulators of neuronal regeneration
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
SI2242769T1 (sl) Protitelesa anti-kadherin-11 EC domene za zdravljenje vnetnih obolenj sklepov
IL206192A0 (en) Modulators of neuronal regeneration
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
WO2012068332A9 (en) Methods for treating early stage or mild neurological disorders
IL202002A0 (en) Method of treating diabetes
EP2219650A4 (en) COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS
ZA200902453B (en) PAI-1 binding modulators for the treatment of ocular disorders